Latest Biotech News

Tempus reported preliminary Q4 revenue up ~83% year‑over‑year and full‑year 2025 revenue of about $1.27 billion, driven by diagnostics and data licensing deals. Guardant Health said preliminary Q4...

Eikon Therapeutics, the high‑profile startup built around protein dynamics technology and led by former Merck executives, filed to go public as it looks to bankroll a clutch of clinical cancer and...

Researchers and commentators reported new advances in delivering genome editors directly to tissues in living organisms. Doudna and colleagues framed a rational design approach for targeted...

Novartis agreed to license a preclinical amyloid-targeting Alzheimer’s program from SciNeuro with a $165 million upfront payment and a joint early-development plan. The deal gives Novartis rights...

The FDA issued another rejection of Atara Biotherapeutics’ tabelecleucel (tab-cel), a T cell therapy for Epstein-Barr virus (EBV)-related complications after transplantation. The agency’s decision...

Parabilis Medicines closed a $305 million Series F financing led by RA Capital, Fidelity and Janus Henderson to advance zolucatetide (FOG-001) toward Phase III for desmoid tumors. The company said...

Kinaset Therapeutics secured $103 million in a Series B round to progress its inhaled candidate for asthma toward late-stage testing. The financing comes five years after the company’s initial...

Mirador Therapeutics closed a $250 million Series B to accelerate its precision-immunology pipeline and signaled plans to consider an IPO later in the year. The financing will support clinical...

Eikon Therapeutics, a protein-dynamics drug developer founded by former Merck executives, signaled plans to go public and to use proceeds to fund a clutch of oncology and neuroscience programs....

Teva Pharmaceuticals agreed a financing arrangement with Royalty Pharma that could provide up to $500 million to support development of TEV-‘408, an anti–IL‑15 antibody being tested for vitiligo....

Tempus reported preliminary fourth-quarter revenue of approximately $367 million, an 83% year-over-year increase driven by diagnostics volume growth in oncology and hereditary disease testing. The...

Guardant Health reported preliminary fourth-quarter revenue of roughly $280 million, a 39% increase year over year driven by higher volumes in oncology testing and rapid uptake of its Shield...

Parabilis Medicines closed a $305 million Series F financing led by RA Capital, Fidelity Management & Research, and Janus Henderson to advance zolucatetide (FOG-001) into Phase III for desmoid...

Eikon Therapeutics outlined plans to go public after raising more than $1 billion in private funding since 2019 and building a drug portfolio from dealmaking and its protein-motion platform. Run...

Mirador Therapeutics closed a $250 million Series B to scale development of precision medicines for immune diseases and signaled consideration of an IPO later this year. The company told Endpoints...

Tempus reported preliminary fourth‑quarter revenue of roughly $367 million, an 83% increase year‑over‑year, citing testing growth as the primary driver and topping Wall Street estimates. The...

Guardant Health reported preliminary Q4 revenue of about $280 million, a 39% year‑over‑year increase that beat estimates, driven by higher volumes in both oncology and screening tests. The company...

Veracyte reported preliminary Q4 revenue between $138 million and $140 million (16–18% growth) and full‑year 2025 revenue of $515–517 million, driven by testing volume gains. The diagnostic firm...

10x Genomics said preliminary Q4 revenue of $166 million — ahead of consensus — with consumables revenue rising about 6% to approximately $141.7 million while instrument revenue declined sharply...

Castle Biosciences expects preliminary full‑year 2025 revenue of $340 million, above prior guidance and consensus, driven by a 37% year‑over‑year increase in test reports. The company delivered...